Multiple Myeloma

Expert oncologists focus on a final patient case of transplant-ineligible newly diagnosed multiple myeloma and reflect on the treatment armamentarium in this setting.

Before closing out their review of treatment for transplant-eligible multiple myeloma, panelists consider how they might adjust therapy to optimize tolerability or efficacy.

Martin Dietrich, MD, PhD, Sara Tolaney, MD, MPH, and Gregory Vidal, MD, PhD review recent data from the TROPiCS-02 trial on sacituzumab govitecan and discuss the clinical implications of these findings.

Amrita Krishnan, MD, and Krina Patel, MD, review promising bispecific agents under investigation for multiple myeloma treatment.

Dr Krina Patel presents the case of a relatively young patient with relapsed multiple myeloma, and Dr Caitlin Costello shares her approaches to treating relapsed/refractory multiple myeloma in her clinical practice.

Drs Tuchman and Gasparetto present two profiles of patients with transplant-ineligible NDMM.

Cristina Gasparetto, MD, details how to assess treatment response and duration of treatment for transplant-eligible NDMM.

A brief review of the role of transplant in patients with newly diagnosed multiple myeloma and how it can be best coupled with systemic treatment.

In a recent Between the Lines, Joshua Richter, MD, and Peter Forsberg, MD, discussed a recent commentary on weekly dosing and supportive care solutions for selinexor in patients with multiple myeloma, and provided a general overview of the agent in this treatment landscape.

Data from a study indicated that durable minimal residual disease negativity was associated with stool butyrate production in patients with multiple myeloma who had plant-based diets undergoing treatment with lenalidomide maintenance.

Shared insight on the optimal selection of induction therapy for patients with high-risk transplant-eligible newly diagnosed multiple myeloma.

Centering discussion on a patient case of transplant-eligible newly diagnosed multiple myeloma, expert panelists define high-risk disease and how it impacts treatment.

The panel explains their goals of treatment for older patients with transplant-ineligible multiple myeloma, and how they determine treatment duration.

Rafael Fonseca, MD, and Krina Patel, MD, discuss the standard treatment approaches for frail or elderly patients with transplant-ineligible multiple myeloma.

Dr Cindy Varga explains the design and results of the MASTER study presented at ASH [American Society of Hematology Annual Meeting] 2021.

Comprehensive insight on mainstay induction therapy options for patients with transplant-eligible newly diagnosed multiple myeloma in the context of recent clinical studies.

Opening their discussion on the first patient case, expert panelists review the management of transplant-eligible newly diagnosed multiple myeloma.

The primary end point of progression-free survival was not met in the phase 3 DREAMM-3 trial which investigated belantamab mafodotin in patients with relapsed/refractory multiple myeloma.

Higher neighborhood socioeconomic status improves long-term survival in patients with multiple myeloma regardless of overlapping disparities between racial and ethnic groups.

A panel of experts in multiple myeloma discusses recent data updates from 2022 International Myeloma Society Annual Meeting and how it influences treatment strategies in clinical practice.

Dr Caitlin Costello presents the case of a patient with transplant-ineligible multiple myeloma and sparks a conversation on the available treatment regimens.

A look at how to measure an adequate treatment response in patients with transplant-ineligible newly-diagnosed multiple myeloma, and treatment regimens for high-risk patients.

A brief discussion on the use of consolidation therapy to improve patient outcomes following transplant in newly diagnosed multiple myeloma.

Expert perspectives on the real-world use of induction therapy and transplant in patients with transplant-eligible newly diagnosed multiple myeloma.

Patients with relapsed/refractory multiple myeloma may benefit from treatment with elranatamab, which was granted breakthrough therapy designation by the FDA.